Preclinical development of lead antibody-radionuclide conjugate targeting L1CAM to treat cancer patients resistant to chemotherapy
Bubendorf, Switzerland, Monday, May 31, 2021 - CIS Pharma and the Paul Scherrer Institute of ETH were granted a two-year research program by Innosuisse to develop an antibody-radionuclide conjugate, ARC, [...]